|
Clinical characteristics' of patients undergoing immunohistochemical analysis and the difference in various parameters between IHC expressed (+ve) and those that did not express IHC markers (-ve) |
|||||||||
| CgA+ve n = 30 |
CgA -ve n = 54 |
p value |
NSE +ve n = 44 |
NSE -ve n = 40 |
p value |
SYN +ve n = 8 |
SYN -ve n = 76 |
p value |
|
|
|
|||||||||
| Age (median ±) |
73.2 ± 6.3 |
69.1 ± 7.4 |
0.22 |
70.3 ± 7.4 |
68.4 ± 7.1 |
0.33 |
70.9 ± 9 |
71.2 ± 8.1 |
0.20 |
|
|
|||||||||
| PSA mean (ng/ml) |
432 |
310 |
0.10 |
606 |
444 |
0.10 |
112 |
412 |
0.01 |
|
|
|||||||||
| Clinical stage Organ Confined |
5 |
12 |
0.03 |
12 |
5 |
0.02 |
2 |
15 |
0.001 |
|
|
|||||||||
| Locally Advanced |
8 |
27 |
0.02 |
12 |
23 |
0.05 |
3 |
32 |
0.001 |
|
|
|||||||||
| Metastatic |
17 |
26 |
0.10 |
20 |
23 |
0.32 |
3 |
40 |
0.001 |
|
|
|||||||||
| Gleason sum (mean) |
6.9 |
6.1 |
0.05 |
6.1 |
7.2 |
0.04 |
7 |
6.3 |
0.22 |
|
CgA: Chromogranin A NSE: Neuron specific enolase SYN: Synaptophysin | |||||||||
Ather et al. BMC Urology 2008 8:21 doi:10.1186/1471-2490-8-21 |
|||||||||